Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
WARS2 antisense RNA 1 (WARS2-AS1)
- Target
- WARS2-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense RNA, Non-coding RNA
01
Overview
WARS2 antisense RNA 1 (WARS2-AS1) is a long non-coding RNA transcribed in the antisense orientation at the WARS2 gene locus. It has been implicated in the regulation of gene expression at both the transcriptional and post-transcriptional levels, typically by forming duplexes with the sense mRNA or influencing chromatin structure. In hepatocellular carcinoma, WARS2-AS1 is upregulated in tumor tissues, and its knockdown increases sensitivity of cancer cells to cuproptosis induced by elesclomol, highlighting its role as a potential therapeutic target and biomarker for prognosis. Like other antisense lncRNAs, the functional effects of WARS2-AS1 may extend to modulation of cell death pathways and regulation of multiple cancer-relevant processes.
- Other names
- WARS2-AS1
02
Mechanism of action
Sensitization to cuproptosis (copper-dependent regulated cell death) via knockdown of WARS2-AS1; Possible regulatory effects on mRNA stability, translation, and chromatin environment typical of antisense lncRNAs
03
Biological functions
Regulation of gene expression through antisense mechanismsModulation of cell death pathways, notably cuproptosis in cancer cellsPossibly alteration of chromatin structure and transcriptional interference (typical for antisense RNAs)
04
Disease associations
Cancer (particularly hepatocellular carcinoma)Possibly other malignancies (role in cell survival mechanisms is a broad area under investigation)
05
Safety considerations
As WARS2-AS1 is a regulatory RNA, therapeutic strategies (e.g., antisense oligonucleotides) present challenges in off-target effects and delivery.Effects on broader gene regulatory networks as seen for lncRNAs and antisense transcripts could have unintended consequences.
06
Interacting drugs
Elesclomol
07
Biomarkers
Expression level of WARS2-AS1 in tumor tissue as a prognostic indicator in hepatocellular carcinoma
Beyond the preview
Go deeper on WARS2 antisense RNA 1 (WARS2-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WARS2 antisense RNA 1 (WARS2-AS1).